Effects of DPP-4 inhibitors on brain natriuretic peptide, neuropeptide Y, glucagon like peptide-1, substance P levels and global longitudinal strain measurements in type 2 diabetes mellitus patients

Authors : Emra ASFUROGLU KALKAN, Berna İmge AYDOĞAN, İrem DINÇER, Sevim GÜLLÜ

Pages : 1424-1430

Doi:10.32322/jhsm.1133314

View : 28 | Download : 14

Publication Date : 2022-09-25

Article Type : Research Paper

Abstract :Introduction: Previously, a significant relationship between saxagliptin treatment and increased rate of hospitalization for congestive heart failure was reported. We aimed to investigate effects of vildagliptin and saxagliptin on brain natriuretic peptide insert ignore into journalissuearticles values(BNP);, neuropeptide Y insert ignore into journalissuearticles values(NPY);, substance P insert ignore into journalissuearticles values(SP);, glucagon like peptide-1 insert ignore into journalissuearticles values(GLP-1); levels and left ventricular global longitudinal strain insert ignore into journalissuearticles values(GLS);, assessed by 3-dimensional speckle tracking echocardiography in uncontrolled type 2 Diabetes mellitus insert ignore into journalissuearticles values(T2DM);. Material and method: Thirty seven uncontrolled T2DM insert ignore into journalissuearticles values(HbA1c>7,5%); patients who were recently prescribed to either vildagliptin 50 mg BID insert ignore into journalissuearticles values(n=21); or saxagliptin 5 mg QD insert ignore into journalissuearticles values(n=16); were included in this study. Levels of BNP, NPY, SP, GLP-1 levels were measured at admission, first and third months of treatment. GLS was measured at admission and third month. Results: In whole group, BNP and NPY values increased significantly at third month of treatment insert ignore into journalissuearticles values(p< 0.001, 0.004; respectively);. In the vildagliptin group, BNP and NPY values increased significantly at third month of treatment insert ignore into journalissuearticles values(p=0.02 and p=0.04, respectively);. In the saxagliptin group only BNP levels increased significantly insert ignore into journalissuearticles values(p=0.015);. In both groups; SP, GLP-1 levels and GLS measurements did not change significantly during follow-up period. Conclusion: The current study demonstrated that treatment with saxagliptin and vildagliptin, was associated with increased levels of BNP and NPY levels. No evidence of subclinical myocardial damage or cardiac dysfunction could be detected by GLS measurements. Since our study population had no previous clinical cardiac disorders, increases in BNP and NPY levels with these two DPP4 inhibitors can be considered as a safety signal.
Keywords : DPP 4 inhibitors, brain natriuretic peptide, neuropeptide Y, substance P, glucagon like peptide 1, 3 dimensional echocardiography